診療科別レジメン参照

(最終更新日:2022/9/9)

呼吸器内科

レジメン名
K-01:AMR
K-02:BEV
K-03:CBDCA+CPT-11
K-04:CBDCA+GEM
K-05:CBDCA+PAC+BEV
K-06:CBDCA+S-1
K-07:CBDCA+VP-16
K-08:CDDP+CPT-11【小細胞】
K-09:CDDP+CPT-11【非小細胞】
K-10:CDDP+GEM
K-11:CDDP+S-1
K-12:CDDP+VNR
K-13:CDDP+VP-16(q21日)
K-14:CDDP+VP-16(q28日/放射線併用)
K-15:CDGP+DOC
K-16:CPT-11
K-17:DOC
K-18:DOC+RAM
K-19:GEM
K-20:NGT
K-21:Nivolumab
K-22:PEM
K-23:PEM+BEV
K-24:PEM+CBDCA
K-25:PEM+CBDCA+BEV
K-26:PEM+CDDP
K-27:PEM+CDDP+BEV
K-28:S-1+BEV
K-29:VNR
K-30:Nivolumab
K-31:weeklyAbraxane+CBDCA
K-32:weeklyPAC+CBDCA
K-33:CAMP
K-34:Pembrolizumab
K-35:Atezolizumab
K-36:Durvalumab
K-37:PEM+CDDP+Pembrolizumab
K-38:PEM+CBDCA+Pembrolizumab
K-39:weeklyAbraxane+CBDCA+Pembrolizumab
K-40:PEM+Pembrolizumab
K-41:PAC+CBDCA+BEV+Atezolizumab
K-42:CBDCA+VP16+Atezolizumab
K-43:weeklyAbraxane+CBDCA+Atezolizumab
K-44:BEV+Atezolizumab
K-45:CDDP+VP-16+Durvalmab
K-46:Durvalumab【小細胞・1500mg】
K-47:PEM+CBDCA+Nivolumab+Ipilimumab
K-48:Nivolumab(360mg day1,22)+Ipilimumab q6w
K-49:CBDCA+PAC+Pembrolizumab
K-50:PEM+CBDCA+Atezolizumab
K-51:PEM+Atezolizumab
K-52:CBDCA+VP-16+Durvalumab
K-53:CBDCA+PAC+Nivolumab+Ipilimumab

 

外科

レジメン名
G-01:XELIRI+BEV
G-02:GEM(2投1休)
G-03:EC
G-04:FEC100
G-05:DOC
G-06:DOC+HER
G-07:DOC+HER+Pertuzumab
G-08:DOC+weeklyHER
G-09:DOC+weeklyHER+Pertuzumab
G-10:Eribulin
G-11:Eribulin+HER
G-12:Eribulin+HER+Pertuzumab
G-13:GEM+tri-weeklyHER+Pertuzumab
G-14:GEM
G-15:GEM+HER
G-16:GEM+weeklyHER
G-17:GEM+weeklyHER+Pertuzumab
G-18:Kadcyla(T-DM1)
G-19:nabPTX+weeklyHER+Pertuzumab
G-20:nabPTX+HER+Pertuzumab
G-21:nabPTX+weeklyHER
G-22:TC(DOC/CPA)
G-23:HER
G-24:HER+Pertuzumab
G-25:VNR
G-26:VNR+HER
G-27:VNR+HER+Pertuzumab
G-28:VNR+weeklyHER
G-29:VNR+weeklyHER+Pertuzumab
G-30:weeklyHER
G-31:weeklyPTX
G-32:weeklyPTX+Bev
G-33:weeklyPTX+weeklyHER
G-34:Pembrolizumab
G-35:nabPAC+Atezolizumab
G-36:CMF
G-37:dose dense EC
G-38:dose dense PTX
G-39:GEM+CBDCA+Pembrolizumab
G-40:nabPTX+Pembrolizumab
G-41:weeklyPTX+Pembrolizumab

 

外科/消化器内科共通

レジメン名
GS-01:mFOLFOX6
GS-02:mFOLFOX6+BEV
GS-03:FOLFIRI
GS-04:FOLFIRI+BEV
GS-05:XELOX
GS-06:XELOX+BEV
GS-07:DCS(DTX/CDDP/S-1)
GS-08:IRIS(q28)
GS-09:IRIS(q21)
GS-10:SOX
GS-11:mFOLFOX6+Pmab
GS-12:FOLFIRI+Pmab
GS-13:Pmab
GS-14:CPT-11(100mg/㎡)(A法)
GS-15:CPT-11(80mg/㎡)2投2休
GS-16:CPT-11(150mg/㎡)
GS-17:SOX+BEV
GS-18:mFOLFOX6+Cmab
GS-19:FOLFIRI+Cmab
GS-20:mDCS+HER
GS-21:XP+HER
GS-22:IRIS+BEV(q28)
GS-23:CPT-11+Pmab
GS-24:nabPTX
GS-25:nabPTX+HER
GS-26:mDCS(DTX/CDDP/S-1)
GS-27:SP
GS-28:SP+HER
GS-29:XP
GS-30:GEM
GS-31:CPT-11+Cmab
GS-32:DOC(60mg/㎡)
GS-33:Cmab
GS-34:FOLFIRI+Aflibercept
GS-35:Pembrolizumab

 

消化器内科

レジメン名
S-01:CDDP+CPT-11
S-02:ECF (EPI/CDDP/5-FU)
S-03:FP
S-04:FP+HER
S-05:MTX+5-FU時間差(LV:注射Ver)
S-06:RAM
S-07:S-1+DTX
S-08:weeklyPTX(80mg/㎡)
S-09:weeklyPTX+RAM
S-12:5-FU/LV (RPMI法)
S-13:FOLFIRI+RAM
S-14:PTX+CBDCA【原発不明がん】
S-15:weeklyPTX 【食道がん】
S-16:術前DCF(DTX/CDDP/5-FU)
S-17:STZ(Daily)
S-18:FOLFIRINOX
S-19:GEM(biweekly)
S-20:nabPTX+GEM
S-21:S-1+GEM
S-22:低用量MTX+VLB【デスモイド腫瘍】
S-23:GC【胆道がん】
S-24:DXR【軟部腫瘍】
S-25:5-FU+CDGP(4000mg/㎡,90mg/㎡)
S-26:CDDP+CPT-11(biweekly)
S-27:UFT+DXR
S-28:DNF-R
S-29:DNF
S-30:Nivolumab
S-31 FP
S-32:nabPTX(weekly)
S-34:5-FU+CDGP(2000mg/㎡,50mg/㎡)
S-35:nabPTX+RAM
S-36:DOC(70mg/㎡)
S-37:GCS
S-38:RAM(肝)
S-39:CPT-11+5-FU[動注]
S-40:SOX+HER
S-41:XELOX+HER
S-42:nal-IRI+5FU/Lv
S-43:GEM+5-FU[動注]
S-44:Pembrolizumab
S-45:mFOLFOXIRI+BEV
S-46:5-FU+Lv+BEV
S-47:BEV+Atezolizumab
S-48:Cmab+Encorafenib+Binimetinib
S-49:Trastuzumab Deruxtecan
S-50:FTD/TPI+BEV
S-51:CPT-11+RAM
S-52:FP+Cmab
S-53:modified FOLFIRINOX
S-54:SOX+Nivolumab
S-55:XELOX+Nivolumab
S-56:FP+Pembrolizumab

 

婦人科

レジメン名
F-01:ADM
F-02:AP (DXR/CDDP)
F-03:BEV (TC+Bev後)
F-04:CBDCA
F-05:CDDP【CCRT】
F-06:CDGP【CCRT】
F-07:CLD-BOMP
F-08:CPT-11
F-09:CPT-11+CDGP
F-10:CPT-11+MMC
F-11:CPT-11+VP-16
F-12:CPT-P (CPT-11/CDDP)
F-13:DN (DOC/CDGP)
F-14:DOC
F-15:DOC+CBDCA
F-16:DOC+GEM
F-17:dose dence-TC(PTX/CBDCA)
F-18:EA (VP-16/ACTD)
F-19:GEM
F-20:GEM+CBDCA
F-21:GEM+CDDP
F-22:IAP (IFM/DXR/CDDP)
F-23:IFM+PTX
F-24:MEA(MTX+VP-16+ACTD)
F-25:TC(PTX/CBDCA)
F-26:MTX
F-27:PLD (Liposomal doxorubicin)
F-28:PTX+CBDCA (CCRT 1回分)
F-29:TC+BEV (PTX/CBDCA/BEV)
F-30:VAC(VCR/ACT-D/CPA)
F-31:weekly PTX
F-32:少量CAP (CPA/THP/CDDP)
F-33:少量連日AP (DXR/CDDP)
F-34:少量連日AP(THP/CDDP)
F-35:少量連日EP (ETP/CDDP)
F-36:EP(ETP+CDDP)
F-37:Eribulin
F-38:DP(DOC+CDDP)
F-39:IFM
F-40:TP(PTX+CDDP)
F-41:TP+BEV (PTX/CDDP/BEV)
F-42:Pembrolizumab
F-43:wPTX+BEV
F-44:NGT
F-45:PLD+CBDCA
F-46:Pembrolizumab+Lenvatinib
F-47:PLD+CBDCA+BEV

 

泌尿器科

レジメン名
U-01:M-VAC
U-02:DOC+PDS
U-03:GC(GEM+CDDP)
U-04:GC(GEM+CDDP)【21日/クール】
U-05:TORISEL
U-06:BEP
U-07:CBDCA
U-08:EP(ETP+CDDP)
U-09:Cabazitaxel+PSL
U-10:TG(PTX+GEM)
U-11:TIP
U-12:GEMOX(GEM+L-OHP)
U-13:Nivolumab
U-14:Pembrolizumab
U-15:GEM+CBDCA
U-16:weekly TC
U-17:Nivolumab+Ipilimumab
U-18:DD-MVAC
U-19:Pembrolizumab+Axitinib
U-20:Avelumab+Axitinib
U-21:Avelumab
U-22:Enfortumab vedotin
U-23:Pembrolizumab+Lenvatinib

 

血液腫瘍内科

レジメン名
ALL-01:L-ASP(維持療法)
ALL-02:Inotuzumab Ozogamicin
ALL-03:Blinatumomab
ALL-202:JALSG Ph+ALL202 寛解導入療法(15-59歳)
ALL-202:JALSG Ph+ALL202 寛解導入療法(60歳以上用)
ALL-202:JALSG Ph+ALL202 地固め療法C1/2
ALL-202 JALSG Ph+ALL202 地固め療法C1/2(60歳以上用)
ALL-202:JALSG Ph+ALL202 維持療法
ALL202-O:JALSG ALL202-O (Over25) Consolidation 【C1/C4】
ALL202-O:JALSG ALL202-O (Over25) Consolidation 【C2A/C5】
ALL202-O:JALSG ALL202-O( Over25) Consolidation 【C2B/C5】
ALL202-O:JALSG ALL202-O(Over25) Induction
ALL202-O:JALSG ALL202-O(Over25) Maintenance
ALL202-O:JALSG ALL202-O(Over25) reinduction 【C3】
AML-01:BHAC-DM
AML-02:CAG
AML-03:FLAGM
AML-04:Gemtuzumab Ozogamicin
AML-05:low dose AraC
AML-06:Venetoclax+AZA(静注)
AML-07:Venetoclax+AZA(皮下注)
AML-08:Venetoclax+ld-AraC
AML-201:JALSG AML201 induction(DNR+AraC)
AML-201:JALSG AML201 induction(IDR+Ara-C)
AML-201:JALSG AML201 Post-remission (AraC大量)
AML-201:JALSG AML201 Post-remission1コース目(MIT+AraC)
AML-201:JALSG AML201 Post-remission2コース目(DNR+AraC)
AML-201:JALSG AML201 Post-remission3コース目(ACR+AraC)
AML-201:JALSG AML201 Post-remission4コース目(A-tripleV)
GML-200:JALSG GML200 Induction Set法
GML-200:JALSG GML200 consolidation 1( MIT+BHAC)
GML-200:JALSG GKL200 consolidation 2 (BHAC+DNR+ETP)
GML-200:JALSG GML200 consolidation 3(BHAC+ACR)
APL-204:JALSG APL204 Consolidation 1コース(MIT/AraC)
APL-204:JALSG APL204 Consolidation 2コース(DNR/AraC)
APL-204:JALSG APL204 Consolidation 3コース(IDR/AraC)
APL-204:JALSG APL204 Induction(GroupB)
APL-204:JALSG APL204 Induction(GroupC)
APL-204:JALSG APL204 Induction(GroupD/移行元GroupA)
APL-204:JALSG APL204 Induction(GroupD/移行元GroupB)
APL-204:JALSG APL204 Induction(GroupD/移行元GroupC)
B-01:ATG
B-02:MCNU
B-03:トラベクテジン
B-04:HLH-2004 initial therapy【前半】
B-04:HLH-2004 initial therapy【後半】
B-04:HLH-2004 continuation therapy
HL-01:ABVd
HL-02:Brentuximab vedotin
HL-03:C-MOPP
HL-04:A-AVD
HL-05:Nivolumab
HL-06:Pembrolizumab
MDS-01:【静注】Azacitidine
MDS-02:【皮下注】Azacitidine
MM-01:BOR(weekly)
MM-02:CyBorD
MM-03:CyBorD(modify)
MM-04:E-Ld(Elotuzumab/LEN/DEX)
MM-05:KRd(Carfilzomib+REN+Dex)
MM-06 VPd 
MM-07:PAD
MM-08:sVRD
MM-09:VAD
MM-10:Kd(Carfilzomib+Dex)
MM-12:VRD
MM-13:DLd
MM-14:DBd
MM-15:RVD lite (寛解導入)
MM-16:*週1回*Kd
MM-17:E-Pd
MM-18:D-VMP
MM-19:IsaPd
MM-20:DLd(皮下注)
MM-21:D-VMP(皮下注)
MM-22:DPd
MM-23:IsaKd
MM-24:Isa単剤
MM-25:Isa+d
NHL-01:Bendamustine (120mg/㎡)
NHL-02:CHASE
NHL-03:CHASER
NHL-04:CHOP
NHL-05:CMD
NHL-06:CPT-11(40mg/㎡)【C法】
NHL-07:DA-EPOCH
NHL-08:DA-EPOCH-R
NHL-09:DeVIC
NHL-10:DeVIC(Reduced)
NHL-11:DHAP
NHL-12:E-CHOP
NHL-13:FCR
NHL-14:GDC
NHL-15:GDP
NHL-16:Hyper-CVAD
NHL-17:ICE(変法)
NHL-18:MA(MTX/AraC)
NHL-19:mLSG15 (VCAP/AMP/VECP)
NHL-20:Mogamulizumab
NHL-21:BR(低悪性度用)
NHL-22:BR(DLBCL用)
NHL-23:R-CHOP
NHL-24:R-CHOP(1日・外来用)
NHL-25:R-CMD
NHL-26:R-DeVIC
NHL-27:R-DHAP
NHL-28:R-GDC
NHL-29:R-GDP
NHL-30:R-hyper-CAVD
NHL-31:R-MA(MTX/AraC)
NHL-32:R-THP-COP
NHL-33:R-THP-COP(1日・外来用)
NHL-34:RTX
NHL-35:SMILE
NHL-36:THP-COP
NHL-37:大量MTX
NHL-38:VR-CAP
NHL-39:VR-CAP(modify)
NHL-41:G-CHOP
NHL-42:G-CVP
NHL-43:G-B
NHL-44:Obinutuzumab維持療法
NHL-45:Romidepsin
NHL-46:R2
NHL-47:Pola+BR
NHL-48:Denileukin Diftitox
NHL-49:R-MPV
NHL-50:Pola-R-CHP
SCT-01:BEA
SCT-02:BEAM
SCT-03:Bor/CY
SCT-04:Bor/L-PAM
SCT-05:チオテパ+ブスルファン(移植前処置)
SCT-06:ID-CY (PBSCH用)
SCT-12:HD-AraC
SCT-13:HD-VP-16
SCT-14:LEED
SCT-15:MCVC
SCT-16:R-HDAraC
SCT-17:R-MCVC